Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for $8.8 Billion
Vertex Pharmaceuticals Incorporated (VRTX) entered a merger agreement on July 6, 2026, to acquire Crinetics Pharmaceuticals, Inc. (CRNX) in a deal valued at $8.8 billion. Deal…
Written byAsif SuriaSource: InsideArbitrage
Vertex Pharmaceuticals Incorporated (VRTX) entered a merger agreement on July 6, 2026, to acquire Crinetics Pharmaceuticals, Inc. (CRNX) in a deal valued at $8.8 billion. Deal Structure: Vertex will acquire all outstanding shares of Crinetics common stock for $85 per share in cash, representing a 102.24% premium on the stock’s last close. Company Profile: Crinetics